DETAILED NOTES ON MOUNJARO INJECTION 2.5 MG

The demo attained both of those its Main endpoints, with semaglutide two.4 mg demonstrating statistically sizeable and superior enhancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in those with MASH compared to placebo.1Pancreatitis and gallbladder tro